Close
  Indian J Med Microbiol
 

Figure 5: Line chart of fingertip blood sugar during the two admission periods. (a) The trends of average and lowest blood sugar of this patient during the first admission. Note that the difference between two values decreased from treatment day 1, indicating a lower frequency of hypoglycemia after the administration of dacarbazine. This clinical benefit persisted even without steroid use after day 9. The relatively lower sugar level on day 11 was considered to be related to the discontinuation of IV dextrose infusion. (B: bevacizumab 200 mg IV infusion 30 min, D10: dextrose 10% IV continuous infusion, DTIC: dacarbazine 200 mg/m2 IV infusion 30 min/day in 5 subsequent days). (b) The trends of average and lowest blood sugar of this patient during the last admission. Despite pazopanib use, there were still many hypoglycemic events before day 129. After gemcitabine and paclitaxel infusion, along with TPN support, his blood sugar improved slightly and the effect lasted for several days. (G: gemcitabine 600 mg/m2 IV infusion 30 min, P: paclitaxel 80 mg/m2 IV infusion 60 min, PPN: peripheral parenteral nutrition, glucose 75 g/L; TPN: total parenteral nutrition, glucose 240 g/L)

Figure 5: Line chart of fingertip blood sugar during the two admission periods. (a) The trends of average and lowest blood sugar of this patient during the first admission. Note that the difference between two values decreased from treatment day 1, indicating a lower frequency of hypoglycemia after the administration of dacarbazine. This clinical benefit persisted even without steroid use after day 9. The relatively lower sugar level on day 11 was considered to be related to the discontinuation of IV dextrose infusion. (B: bevacizumab 200 mg IV infusion 30 min, D10: dextrose 10% IV continuous infusion, DTIC: dacarbazine 200 mg/m<sup>2</sup> IV infusion 30 min/day in 5 subsequent days). (b) The trends of average and lowest blood sugar of this patient during the last admission. Despite pazopanib use, there were still many hypoglycemic events before day 129. After gemcitabine and paclitaxel infusion, along with TPN support, his blood sugar improved slightly and the effect lasted for several days. (G: gemcitabine 600 mg/m<sup>2</sup> IV infusion 30 min, P: paclitaxel 80 mg/m<sup>2</sup> IV infusion 60 min, PPN: peripheral parenteral nutrition, glucose 75 g/L; TPN: total parenteral nutrition, glucose 240 g/L)